Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Klauder JV. Intravenous injections of bismuth compounds in the treatment of syphilis: its use clinically and in experimental syphilis in rabbits. Arch Derm Syphilol. 1928;17(3):332-350. doi: 10.1001/archderm.1928.02380090041006.
Canadian Agency for Drugs and Technologies in Health. Bismuth Salts for Gastrointestinal Issues: A Review of the Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Nov 24.
Abaturov AE, Gerasimenko ON, Zavgorodniaia NIu. Khronicheskie SagA+NR-assotsiirovannye gastrity u detei [Chronic CagA + HP-associated gastritis in children]. Kharkiv: SAM; 2014. 399 p. (in Russian).
Hermann WA, Herdtweck E, Pajdla L. Colloidal Bismuth Subcitrate (CBS): Isolation and structural characterization of the active substance against Helicobacter pylori, a causal factor of gastric diseases. Inorg Chem. 1991;30(12):2579-2581. doi: 10.1021/ic00012a001.
Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015 Oct;42(7):922-33. doi: 10.1111/apt.13346.
Armstrong JA, Cooper M, Goodwin CS, et al. Influence of soluble haemagglutinins on adherence of Helicobacter pylori to HEp-2 cells. J Med Microbiol. 1991 Mar;34(3):181-7. doi: 10.1099/00222615-34-3-181.
Yang X, Koohi-Moghadam M, Wang R, et al. Metallochaperone UreG serves as a new target for design of urease inhibitor: A novel strategy for development of antimicrobials. PLoS Biol. 2018 Jan 10;16(1):e2003887. doi: 10.1371/journal.pbio.2003887.
AlMatar M, Makky EA, Var I, Koksal F. The Role of Nanoparticles in the Inhibition of Multidrug-Resistant Bacteria and Biofilms. Curr Drug Deliv. 2018;15(4):470-484. doi: 10.2174/1567201815666171207163504.
Ma L, Wu J, Wang S, Yang H, Liang D, Lu Z. Synergistic antibacterial effect of Bi2S3 nanospheres combined with ineffective antibiotic gentamicin against methicillin-resistant Staphylococcus aureus. J Inorg Biochem. 2017 Mar;168:38-45. doi: 10.1016/j.jinorgbio.2016.12.005.
Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168.
Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052. doi:10.1136/bmj.h4052.
Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):991-1003. doi: 10.1097/MPG.0000000000001594.
Ministry of Нealth of Ukraine. Order on January 29, 2013 № 59. On Adopting the Standardized Clinical Protocols of Medical Care for Children with Diseases of the Digestive Organs. Available from: http://zakon.rada.gov.ua/rada/show/v0059282-13?lang=en. Accessed: January 29, 2013. (in Ukrainian).